New combo therapy shows promise for inoperable lung cancer
NCT ID NCT02599454
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a combination of an immunotherapy drug (atezolizumab) and precise radiation therapy (SBRT) in 20 people with stage I non-small cell lung cancer who couldn't have surgery. The main goal was to find the safest dose and check for side effects. Researchers also looked at how long patients stayed cancer-free and whether tumors shrank.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (a drug that helps the immune system fight cancer) and stereotactic body radiation therapy (high-precision radiation)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with early-stage lung cancer who cannot have surgery.
What could go wrong
This is a very early (phase I) trial with only 20 participants, so results may not apply to everyone. The main goal was safety, not yet proving the treatment works better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE I NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
David Grant United States Air Force Medical Center
Travis AFB, California, 94535-1800, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States